Role of hydroxyurea therapy in the prevention of organ damage in sickle cell disease: a systematic review and meta-analysis

Table 3 Splenic abnormality in SCD patients on hydroxyurea therapy and not on hydroxyurea therapy

Sr.no	Authors with year of publication	Total number of SCD patients	Splenic uptake abnormality at baseline^ab	Splenic uptake abnormality after hydroxyurea treatment	Hydroxyurea dose	Duration of hydroxyurea therapy (years)
1	Hankins JS et al. 2008 [36]	43	95%	81.40%	MTD up to 30–35 mg/kg/day	2.6
2	Hankins JS et al. 2005 [59]	14	NA	78.50%	30 mg ± 1.2 mg/kg/day	4
3	Nottage KA et al. 2014 [57]	40	77·50%	67.50%	20 mg escalated to MTD	3
4	Wang WC et al. 2001 [37]	17	100%	94.11%	20 mg/kg/day	2
5	Santos A et al. 2002 [56]	21	100%	92.85	15 mg/kg/day with dose escalation	1
6	Wang WC et al. 2011 [60]	144	38%	27%	20 mg/kg/day	2

Any gain in spleen function after hydroxyurea treatment is considered as normal splenic function
^aAt baseline or in the non-hydroxyurea group/placebo group
^bDecline in splenic uptake from normal to decreased or absent, or from decreased to absent)

ISSN: 2046-4053